Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dass, S., et al. - The B cell-depleting monoclonal antibody rituximab is a novel therapy for the rheumatic diseases, with an increasing body of evidence regarding its safety and efficacy in an expanding range of indications. However, there is uncertainty over its potential use in, and impact on, autoantibody-negative diseases. We describe 3 patients, with no known risk factor for psoriasis, who developed psoriasis (and 1 who also developed features of psoriatic arthritis) after receiving rituximab for a variety of indications, namely, seropositive and seronegative rheumatoid arthritis and systemic lupus erythematosus

Today in Amyloidosis...keeping you current

Amyloid and the GI tract
Expert Review of Gastroenterology & Hepatology, 12/03/09

MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations
Rheumatology International, 10/16/09

Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens
Blood, 10/09/09

Today in Gout and Hyperuricemia...keeping you current

Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease
PLoS ONE - Cardiovascular Disorders, 11/10/09

The modern management of gout
Rheumatology, 10/08/09

Hyperuricemia Is a Mediator of Endothelial Dysfunction and Inflammation in Renal Allograft Recipients
Transplantation Proceedings, 11/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address